Total artificial heart--concepts and clinical use.

Area of Science:

• Cardiology
• Medical Devices
• Surgical Innovation

Background:

• End-stage congestive heart failure (CHF) is a primary cause of mortality and hospital admissions in the US.
• Orthotopic heart transplantation, the current gold standard, faces limitations due to donor organ scarcity and patient eligibility.
• Existing ventricular assist device (VAD) therapy primarily targets left ventricular failure and has associated complications.

Purpose of the Study:

• To address the unmet need for advanced cardiac support in patients ineligible for transplantation.
• To evaluate the role of total artificial hearts in managing biventricular failure.
• To improve survival and quality of life for end-stage cardiac patients.

Main Methods:

• Review of current therapeutic options for end-stage heart failure.
• Analysis of the application and limitations of existing VAD technology.
• Assessment of the emerging role of total artificial hearts for biventricular support.

Main Results:

• Ventricular assist device (VAD) therapy has been adopted to extend survival and enhance quality of life for end-stage cardiac patients.
• Current VADs are primarily limited to left ventricular support and present long-term use challenges.
• The total artificial heart, utilizing two devices, is increasingly favored for biventricular failure.

Conclusions:

• Total artificial hearts represent a significant advancement for patients with biventricular failure.
• This technology offers a viable alternative for patients not suitable for heart transplantation.
• Further development and application of total artificial hearts are crucial for managing advanced heart failure.